Phase I clinical trials in RA patients treated with Jusvinza showed a reduction on blood ACPA levels DAS28 score and achievement of ACR50 and ACR70 in 6 months (200, 201). This evidence concerns the gene PRTN3 and rheumatoid arthritis.